Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

Launched by BIOCRYST PHARMACEUTICALS · Aug 3, 2017

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Able to provide written, informed consent.
• • 2. A clinical diagnosis of hereditary angioedema Type 1 or Type 2 as documented at any time in the medical records or at the screening visit.
• • 3. Access to and ability to use standard of care acute attack treatment for attacks of HAE.
• • 4. Sexually active women of child-bearing potential and sexually active men must utilize effective contraception.
• Exclusion Criteria:
• • 1. Women who are pregnant or breast-feeding.
• • 2. Any clinical condition or medical history that would interfere with the subject's safety or ability to participate in the study.
• • 3. Use of C1INH, androgens or tranexamic acid for prophylaxis of HAE attacks.
• • 4. History of or current alcohol or drug abuse.
• • 5. Infection with hepatitis B, hepatitis C or HIV.
• • 6. Participation in any other investigational drug study currently or within the last 30 days.
• • 7. Positive drugs of abuse screen (unless as used as medical treatment, e.g., with a prescription).
• • 8. An immediate family relationship to either Sponsor employees, the Investigator or employees of the study site.